ARF6 plays a critical role in pathologic protein trafficking in conditions as seemingly diverse as acute lung injury and melanoma. A6 Pharmaceuticals has identified proprietary small molecule inhibitors of ARF6. Using these compounds, we have demonstrated efficacy in in vivo models of disease including uveal melanoma, malignant sarcoma, acute lung injury/acute respiratory distress syndrome, multi-drug resistant gram negative bacterial pneumonia, and diabetic retinopathy.
A6 is aggressively advancing its lead program in acute respiratory distress syndrome through IND and into Phase 1 safety and proof of concept, and its pancreatic cancer program through proof of concept in animals and into IND-enabling studies.
A6 is guided by a team of senior managers, scientists, directors, and advisors with extensive experience in the pharma industry, finance, regulatory affairs, clinical practice, and basic research.